137 related articles for article (PubMed ID: 7670409)
1. Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT.
Bassan R; Cortelazzo S; Rambaldi A; Cornelli P; Borleri G; Bellavita P; Biondi A; Barbui T
Bone Marrow Transplant; 1995 May; 15(5):791-3. PubMed ID: 7670409
[TBL] [Abstract][Full Text] [Related]
2. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
5. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P
Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972
[TBL] [Abstract][Full Text] [Related]
6. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
7. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report.
Berger M; Ferrero I; Vassallo E; Gastaldo L; Carraro F; Biasin E; Madon E; Fagioli F
Pediatr Hematol Oncol; 2005; 22(7):597-608. PubMed ID: 16166053
[TBL] [Abstract][Full Text] [Related]
8. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse.
Soiffer RJ; Roy DC; Gonin R; Murray C; Anderson KC; Freedman AS; Rabinowe SN; Robertson MJ; Spector N; Pesek K
Bone Marrow Transplant; 1993 Sep; 12(3):243-51. PubMed ID: 8241984
[TBL] [Abstract][Full Text] [Related]
10. Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy.
Meloni G; De Fabritiis P; Carella AM; Mangoni L; Porcellini A; Marmont A; Mandelli F
Bone Marrow Transplant; 1990 Jan; 5(1):29-32. PubMed ID: 2404528
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
13. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
14. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Matsue K; Tohi T; Masauji N; Tsukuda K
Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
[TBL] [Abstract][Full Text] [Related]
15. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia.
Damon LE; Rugo HS; Ries CA; Linker CA
Bone Marrow Transplant; 1996 Jan; 17(1):93-9. PubMed ID: 8673063
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
[TBL] [Abstract][Full Text] [Related]
17. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
18. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
[TBL] [Abstract][Full Text] [Related]
19. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
20. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
